In cervical, prostate, and lung cancers, fascin expression has been associated with resistance to cisplatin, paclitaxel, and docetaxel, often through EMT-linked mechanisms or miRNA dysregulation [114,132,133]. This evidence concerns the gene FSCN1 and lung carcinoma.